Is GHK-Cu Safe? Is It FDA Approved?

GHK-Cu is not FDA-approved as a drug for any indication in the United States; its classification is research-use only. No company has completed the Phase III human trials and New Drug Application that approval requires — which is a statement about investment and process, not a verdict that it's unsafe or illegal.

The landscape did shift in April 2026: the FDA removed injectable GHK-Cu from the Category 2 list that had blocked compounding, so licensed 503A compounding pharmacies can now prepare it with a prescription. Non-injectable routes are being removed from Category 1. Both are scheduled for Pharmacy Compounding Advisory Committee (PCAC) review before February 2027. Importantly, a compounding pathway is not the same as drug approval.

In research and community reports, GHK-Cu is generally described as well tolerated, with effects that are mostly mild, local, and transient. The 2020 pharmacokinetic study mentioned above found no elevation in serum copper or ceruloplasmin over 12 weeks of daily use, and the estimated margin between typical research amounts and a toxic dose is very wide. For a full breakdown of what researchers report, see our GHK-Cu side effects article.

The honest caveats: there are limited large-scale, long-term human trials; copper accumulation can't be fully excluded with prolonged use or in people with impaired copper metabolism (Wilson's disease); and a mild, temporary blood-pressure-lowering effect has been reported anecdotally.

Because GHK-Cu is sold as a research-grade material, purity and sourcing vary widely between suppliers — and in practice that variation is a bigger real-world risk than the peptide itself.

What researchers look for: a recent third-party certificate of analysis (COA), HPLC-verified purity, proper reconstitution with bacteriostatic water, and sterile handling. Under-dosed, over-dosed, or contaminated material is the failure mode to guard against.